



Reply and Amendment
U.S. Serial No. 09/292,053
Attorney Docket No. 037003-0275739

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re Patent Application of:)
Mitchell E. Reff, et al.)
Application No. 09/292,053)
Filed: April 14, 1998)
For: GAMMA-1 ANTI-HUMAN CD23)
MONOCLONAL ANTIBODIES)
AND USE THEREOF AS)
THERAPEUTICS)

RECEIVED

NOV 01 2002

TECH CENTER 1600/2900

Group Art Unit: 1644

Examiner: M. DiBrino

REPLY AND AMENDMENTS PURSUANT TO 37 CFR §1.116

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action [final rejection] kindly amend the above-identified application as follows:

IN THE SPECIFICATION

Kindly amend the disclosure as follows:

Page 47, first paragraph

The first PCR amplification of the light chain of the light chain variable region from the cDNA of the primate monoclonal antibody 6G5 showed bands which were consistent in situ with the lambda light chain variable region. These bands appeared in all reactions using the three different early leader sequence primers. (See Tables 1-3.) [SEQ ID NOS: 9-25] However, the PCR product obtained using primer 745 (Family 2) was considered more specific because of the relatively greater intensity of the PCR product band.